Experts Issue 12 Consensus Recommendations to Prevent Mucormycosis After Viral Infections

Mucormycosis, one of the most aggressive invasive fungal infections known to medicine, has moved to the center of international attention once again. A newly published expert consensus, coordinated by West China Hospital of Sichuan University and published in the journal iFungi, sets out twelve formal recommendations designed to prevent secondary mucormycosis in patients recovering from respiratory viral infections such as influenza and COVID-19. The document arrives five years after the world witnessed an unprecedented surge of COVID-19-associated mucormycosis, particularly in India, where more than 50,000 cases and over 4,000 deaths were reported in 2021 alone. That episode demonstrated that viral respiratory illness can create a permissive environment for fungi that ordinarily pose little threat to healthy individuals, and it exposed a striking gap in clinical guidance: while diagnostic and treatment guidelines for mucormycosis already existed, no comparable framework addressed prevention.

The biology behind the problem is deceptively simple. Mucorales, the order of molds responsible for mucormycosis, are ubiquitous in the environment, abundant in air, soil and water, and encountered constantly in daily life. In an immunologically intact host, inhaled spores are dispatched swiftly by innate immune defenses, particularly airway epithelial barriers, alveolar macrophages and neutrophils. Respiratory viral infections disrupt this arrangement at multiple levels. Viral replication damages the respiratory epithelium, stripping away the physical barrier that prevents fungal access to deeper tissue. At the same time, antiviral immune responses and the treatments used to modulate them, most notably systemic corticosteroids and other immunosuppressive agents, can blunt the very cellular machinery required to kill fungal hyphae. The result is a window of vulnerability in which an environmental mold can establish rapidly progressive, angioinvasive disease with high mortality.

Recognizing that this vulnerability is predictable, an international panel set out to define who is most at risk and what can realistically be done to protect them. The effort was coordinated from West China Hospital, Sichuan University, and brought together 49 experts drawn from 44 institutions across eight countries. The panel conducted systematic searches of PubMed, Embase, the Cochrane Library, CNKI and the Wanfang Database through February 2025, and then evaluated proposed statements on high-risk groups and preventive measures through a two-round modified Delphi process, a structured method for building consensus among experts independent of geography and specialty. The threshold for adoption was set at 80 percent agreement. In the event, after revisions between rounds, all twelve final recommendations achieved 100 percent agreement, a level of unanimity that underscores how uncontroversial the core preventive principles are, even where the underlying evidence remains thin. Evidence for each statement was graded using the 2009 Oxford Centre for Evidence-Based Medicine system.

A central contribution of the consensus is its explicit definition of the populations that should be considered at principal risk. Four groups are identified. The first comprises critically ill patients requiring mechanical ventilation, in whom prolonged intubation, sedation and intensive care environments converge with severe illness. The second encompasses immunocompromised patients, a category that includes individuals with poorly controlled diabetes, hematological disease, solid organ or stem cell transplantation, ongoing immunosuppressive treatment and uncontrolled HIV/AIDS. The third consists of patients with stage 4 or 5 chronic kidney disease, a population whose impaired immune function and frequent hospital exposure elevate susceptibility. The fourth covers patients with structural lung disease, such as bronchiectasis, in whom the architectural damage to airways provides both a portal of entry and a reservoir where inhaled spores can persist. Beyond these principal groups, the panel noted that several factors may further increase risk: solid tumors and anticancer treatment, exposure to mold-contaminated environments, prolonged central oxygen use, broad-spectrum antibiotics combined with invasive procedures, and severe malnutrition.

The twelve recommendations are organized into four thematic blocks. Recommendations one through four address education and personal protection. High-risk patients and their families should be informed about exposure risks and practical preventive measures, while healthcare workers should be trained to recognize vulnerable patients and the early warning signs of invasive fungal disease. Vaccination against influenza and COVID-19 is recommended for high-risk patients whenever not contraindicated, a measure that reduces the likelihood of the inciting viral illness itself. Mask use in public settings is advised according to local guidance and availability, reflecting the reality that recommendations must be implementable in widely varying health systems rather than only in well-resourced tertiary centers.

Recommendations five through seven target the timeliness of diagnosis and antiviral therapy, the point at which prevention intersects most directly with clinical practice. Patients with suspected respiratory infection should be tested promptly, with particular attention to influenza virus and SARS-CoV-2, and effective antiviral treatment should begin early. The consensus goes a step further for influenza season: high-risk patients presenting with influenza-like illness may receive empiric antiviral treatment before laboratory confirmation is available, an acknowledgment that delays in testing should not translate into delays in protecting the airway epithelium and preserving antifungal immunity. On the diagnostic infrastructure side, tertiary hospitals are expected to provide testing capability for mucormycosis itself, while secondary hospitals should establish testing services, specimen-transfer arrangements or referral pathways so that suspected cases are not lost in transit between levels of care.

Recommendations eight through eleven concern hospital infection control, an area where mucormycosis prevention differs in practical detail from many other nosocomial threats. Because Mucorales thrive in soil and organic matter, soil-containing items should be excluded from rooms housing high-risk patients, and vulnerable individuals should be protected from dust generated by construction and renovation work, a recognized source of fungal spore aerosols in healthcare facilities. Bed linen should be handled gently to avoid dispersing spores into the air and transported in closed containers. Ventilation systems require proper maintenance to ensure that air handling does not become a vector for fungal dissemination. Standard precautions apply to patients with confirmed mucormycosis, and when a suspected healthcare-associated outbreak occurs, the panel recommends systematic investigation of non-sterile products, invasive procedures and environmental sources, the three routes by which hospital outbreaks of mucormycosis have historically been traced.

The twelfth recommendation addresses the resource-limited settings where the burden of disease is often greatest and where sophisticated diagnostic and air-handling infrastructure may be unavailable. The panel prioritizes screening of high-risk patients, direct microscopy and other affordable diagnostic tests, referral and teleconsultation networks, training for primary healthcare workers, hand hygiene, diabetes management and environmental education. This tiered approach reflects a deliberate design choice: rather than prescribing a single standard that only wealthy health systems could meet, the consensus offers a ladder of interventions that can be adapted to local capacity. Given that the 2021 Indian outbreak unfolded largely in settings of variable resources, this pragmatism is likely to determine the document’s real-world influence.

Notably, the panel declined to recommend routine antifungal prophylaxis for all high-risk patients, a decision that will attract scrutiny given the severity of the disease. Patients with hematological malignancies may be assessed individually according to existing invasive fungal disease guidelines, but the consensus states plainly that current evidence is insufficient to define specific indications, drug choice, timing, dose or duration of prophylaxis following respiratory viral infection. Evidence gaps also extend to immunomodulatory treatment, filtration in central oxygen systems and formal risk-prediction models, all of which remain promising but unvalidated. The authors are candid about the limitations of their evidence base: most available data are retrospective or observational, and the clinical effects of several recommendations require prospective and real-world validation. They identify surveillance, faster diagnostics, environmental monitoring, validated early-warning models and carefully designed prophylaxis studies as the priority research agenda.

The consensus, published as Qu and colleagues in iFungi with corresponding authors including Zhiyong Zong, Junyan Qu and Xinyao Liu of West China Hospital, was supported by the National Key Research and Development Program of China, and all participating experts declared no conflicts of interest. Its significance lies less in any single novel intervention than in its framing: it defines precisely which patients require targeted prevention after respiratory viral infection and translates limited evidence into actionable steps that hospitals and primary care systems can adapt. As respiratory viruses continue to circulate globally and immunosuppressive therapies expand, the document offers clinicians a structured answer to a question that the COVID-19 era made impossible to ignore, namely how to stop an environmental mold from exploiting the damage a virus leaves behind.

Subject of Research: Prevention of secondary mucormycosis following respiratory viral infections

Article Title: Expert consensus outlines 12 recommendations to prevent secondary mucormycosis after respiratory viral infections

Article References: Expert consensus outlines 12 recommendations to prevent secondary mucormycosis after respiratory viral infections. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: mucormycosis, Mucorales, respiratory viral infections, COVID-19, influenza, expert consensus, infection control, immunocompromised patients, antifungal prophylaxis, Delphi process, diabetes, hospital hygiene